| Literature DB >> 30127627 |
Mansour Amin1,2, Mehrandokht Sirous2, Hazhir Javaherizadeh3,4,5, Mohammad Motamedifar6,7, Morteza Saki2,8, Hojat Veisi2, Saeedeh Ebrahimi1,9, Sakineh Seyed-Mohammadi2,8, Mohammad Hashemzadeh1,2.
Abstract
INTRODUCTION: Enteroaggregative Escherichia coli (EAEC) has been implicated as an emerging cause of traveler's diarrhea, persistent diarrhea among children, and immunocompromised patients. The present study aimed to investigate the prevalence of antibiotic resistance, extendedspectrum β-lactamase (ESBL) production, and virulence factors of EAEC isolates obtained from Iranian children suffered from diarrhea.Entities:
Keywords: ESBLs; Iran; adherence; antibiotic resistance; diarrhea; enteroaggregative Escherichia coli
Year: 2018 PMID: 30127627 PMCID: PMC6089113 DOI: 10.2147/IDR.S167271
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
List of used primers in the present study
| Primer | Oligonucleotide sequence (5′ to 3′) | Gene | Product size | Annealing | Reference |
|---|---|---|---|---|---|
| pCVD-F | CTGGCGAAAGACTGTATCAT | 630 | 57 | ||
| pCVD-R | AATGTATAGAAATCCGCTGTT | ||||
| aggR-F | GTATACACAAAAGAAGGAAGC | 254 | 57 | ||
| aggR-R | ACAGAATCGTCAGCATCAGC | ||||
| aggA-F | TTAGTCTTCTATCTAGGG | 457 | 49 | ||
| aggA-R | AAATTAATTCCGGCATGG | ||||
| aafA-F | TGCGATTGCTACTTTATTAT | 242 | 56 | ||
| aafA-R | ATTGACCGTGATTGGCTTCC | ||||
| aap-F | CTTGGGTATCAGCCTGAATG | 310 | 58 | ||
| aap-R | AACCCATTCGGTTAGAGCAC | ||||
| astA-F | CCATCAACACAGTATATCCGA | 111 | 58 | ||
| astA-R | GGTCGCGAGTGACGGCTTTGT | ||||
| TEM-F | GAGTATTCAACATTTCCGTGTC | 800 | 60 | ||
| TEM-R | TAATCAGTGAGGCACCTATCTC | ||||
| PER-F | AATTTGGGCTTAGGGCAGAA | 925 | 48 | ||
| PER-R | ATGAATGTCATTATAAAAGC | ||||
| CTX-M-F | CGCTTTGCGATGTGCAG | 550 | 60 | ||
| CTX-M-R | ACCGCGATATCGTTGGT | ||||
| SHV-F | CGCCTGTGTATTATCTCCCTGTTAGCC | 843 | 62 | ||
| SHV-R | TTGCCAGTGCTCGATCAGCG |
Figure 1The AA pattern of EAEC to HEp-2 cells after 3 h of incubation.
Abbreviations: EAEC, enteroaggregative Escherichia coli; AA, aggregative adherence.
The distribution of virulence and extended-spectrum β-lactamase (ESBL) genes
| Virulence genes | Positive, N (%) | Negative, N (%) |
|---|---|---|
| 21 (65.6) | 11 (34.4) | |
| 0 | 32 (100) | |
| 7 (21.9) | 25 (78.1) | |
| 31 (96.9) | 1 (3.1) | |
| 0 | 32 (100) | |
|
| ||
|
| ||
| 6 (18.7) | ||
| 21 (65.6) | ||
| 4 (12.5) | ||
|
| ||
|
| ||
| 28 (87.5) | 4 (12.5) | |
| 21 (65.6) | 11 (34.4) | |
| 0 | 32 (100) | |
| 0 | 32 (100) | |
| 17 (53.1) | 15 (46.9) | |
The antibiotic susceptibility testing results of 32 EAEC isolates
| Antibiotic | Total EAEC, N (%)
| ESBL producing EAEC, N (%)
| ||||
|---|---|---|---|---|---|---|
| R | I | S | R | I | S | |
| Gentamicin | 10 (31.2) | 0 | 22 (68.8) | 6 (26.1) | 0 | 17 (73.9) |
| Amikacin | 4 (12.5) | 1 (3.1) | 27 (84.4) | 3 (13) | 1 (4.3) | 19 (82.6) |
| Ciprofloxacin | 6 (18.8) | 1 (3.1) | 25 (78.1) | 5 (21.7) | 1 (4.3) | 17 (73.9) |
| Cefoxitin | 5 (15.6) | 0 | 27 (84.4) | 0 | 0 | 23 (100) |
| Ceftazidime | 17 (53.1) | 4 (12.5) | 11 (34.4) | 12 (52.2) | 3 (13) | 8 (34.8) |
| Cefotaxime | 26 (81.3) | 0 | 6 (18.8) | 20 (87) | 0 | 3 (13) |
| Cefpodoxime | 26 (81.3) | 0 | 6 (18.8) | 20 (87) | 0 | 3 (13) |
| Cefteriaxon | 26 (81.3) | 1 (3.1) | 5 (15.6) | 21 (91.3) | 0 | 2 (8.7) |
| Ampicillin | 32 (100) | 0 | 0 | 23 (100) | 0 | 0 |
| Meropenem | 3 (9.4) | 3 (9.4) | 26 (81.3) | 1 (4.3) | 2 (8.7) | 20 (87) |
| Imipenem | 0 | 0 | 32 (100) | 0 | 0 | 23 (100) |
| Tetracycline | 15 (46.9) | 0 | 17 (53.1) | 7 (30.4) | 0 | 16 (69.6) |
| Trimethoprim/sulfamethoxazole | 32 (100) | 0 | 0 | 23 (100) | 0 | 0 |
| Azithromycin | 25 (78.1) | 0 | 7 (21.9) | 18 (78.3) | 0 | 5 (21.7) |
Abbreviations: EAEC, enteroaggregative Escherichia coli, ESBL, extended-spectrum β-lactamase.
Antibiotic resistance phenotypic patterns of EAEC isolates
| Resistance pattern | Phenotypic resistance | Number of resistant EAEC isolates (%) |
|---|---|---|
| I | AMP-SXT | 1 (3.1%) |
| II | AMP-TET-SXT | 2 (6.2%) |
| III | AMP-TET-SXT-AZM | 1 (3.1%) |
| IV | GEN-CTX-CPDX-AMP-CRO-SXT-AZM | 1 (3.1%) |
| V | GEN-CTX-CPDX-AMP-TET-SXT-AZM | 1 (3.1%) |
| VI | GEN-AN-CIP-AMP-CRO-SXT-AZM | 1 (3.1%) |
| VII | GEN-CAZ-CTX-CPDX-AMP-CRO-SXT-AZM | 3 (9.3%) |
| VIII | GEN-CIP-CAZ-CTX-CPDX-AMP-CRO-SXT-AZM | 1 (3.1%) |
| IX | GEN-FOX-CAZ-CTX-CPDX-AMP-CRO-TET-SXT-AZM | 1 (3.1%) |
| X | GEN-FOX-CAZ-CTX-CPDX-MEM-AMP-CRO-TET-SXT-AZM | 2 (6.2%) |
| XI | CTX-CPDX-AMP-CRO-SXT | 1 (3.1%) |
| XII | CTX-CPDX-AMP-CRO-SXT-AZM | 4 (12.5%) |
| XIII | CTX-CPDX-AMP-CRO-TET-SXT-AZM | 2 (6.2%) |
| XIV | AN-AMP-TET-SXT-AZM | 1 (3.1%) |
| XV | AN-CAZ-CTX-CPDX-MEM-AMP-CRO-SXT | 1 (3.1%) |
| XVI | AN-CAZ-CTX-CPDX-AMP-CRO-SXT-AZM | 1 (3.1%) |
| XVII | CIP-CAZ-CTX-CPDX-AMP-CRO-SXT-AZM | 3 (9.3%) |
| XVIII | CIP-FOX-CAZ-CTX-CPDX-AMP-CRO-TET-SXT-AZM | 1 (3.1%) |
| XIX | CAZ-CTX-CPDX-AMP-CRO-TET-SXT | 2 (6.2%) |
| XX | CAZ-CTX-CPDX-AMP-CRO-TET-SXT-AZM | 1 (3.1%) |
| XXI | FOX-CAZ-CTX-CPDX-AMP-CRO-TET-SXT-AZM | 1 (3.1%) |
Abbreviations: EAEC, enteroaggregative Escherichia coli; AMP, ampicillin; AN, amikacin; AZM, azithromycin; CTX, cefotaxime; CRO, ceftriaxone; CAZ, ceftazidime; CPDX, cefpodoxime; CIP, ciprofloxacin; FOX, cefoxitin; GEN, gentamicin; MEM, meropenem; SXT, trimethoprimsulfamethoxazole; TET, tetracycline.
The detailed results of virulence genes, MDR, and ESBL gene patterns in the 32 EAEC isolates
| EAEC No. | Virulance gene profile | MDR pattern | ESBL phenotype | ESBL gene patter |
|---|---|---|---|---|
| 1 | pCVD-astA-aap | II | POS | TEM, CTX-M |
| 2 | pCVD-aap | IV | POS | TEM, CTX-M |
| 3 | pCVD-aap | II | NEG | TEM, CTX-M |
| 4 | astA | IX | NEG | TEM |
| 5 | pCVD-aap | XII | POS | CTX-M |
| 6 | pCVD-aap | XIV | NEG | TEM |
| 7 | pCVD-aap | XI | POS | TEM, CTX-M |
| 8 | pCVD-astA-aap | XV | POS | TEM, CTX-M |
| 9 | astA -aap | V | NEG | TEM |
| 10 | pCVD-aap | XVII | POS | CTX-M |
| 11 | pCVD-aap | I (not MDR) | NEG | TEM, CTX-M |
| 12 | pCVD-aap | XIX | POS | TEM, CTX-M |
| 13 | pCVD-aap | XVII | POS | TEM, CTX-M |
| 14 | pCVD-aap | III | POS | TEM |
| 15 | aap | X | NEG | TEM |
| 16 | pCVD-aap | XX | POS | TEM, CTX-M |
| 17 | pCVD-aap | VI | POS | TEM, CTX-M |
| 18 | pCVD-aap | VII | POS | TEM, CTX-M |
| 19 | pCVD-aap | VIII | POS | TEM |
| 20 | aap | XVIII | NEG | CTX-M |
| 21 | pCVD-aap | XVII | POS | TEM |
| 22 | pCVD-astA-aap | XIII | POS | TEM |
| 23 | aap | XXI | NEG | TEM, CTX-M |
| 24 | aap | XIX | POS | TEM, CTX-M |
| 25 | aap | X | NEG | TEM |
| 26 | aap | XII | POS | CTX-M |
| 27 | astA -aap | XII | POS | TEM, CTX-M |
| 28 | aap | XII | POS | TEM, CTX-M |
| 29 | pCVD-astA-aap | XIII | POS | TEM |
| 30 | aap | VII | POS | TEM, CTX-M |
| 31 | pCVD-aap | VII | POS | TEM |
| 32 | pCVD-aap | XVI | POS | TEM,CTX-M |
Abbreviations: EAEC, enteroaggregative Escherichia coli; ESBL, extended-spectrum β-lactamase; MDR, multiple-drug resistant.